Amneal Pharmaceuticals AMRX · NASDAQ
$21.28 +5.66% (+$1.14)
Summary
47 / 100 · Bulios Score
What speaks for it
- Revenue grew by 11% a year over the last 3 years.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- The share price is above the Bulios Fair Price.
- Repaying its net debt would take 4.7 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 50.2 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 8.7% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 5.9%.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 60 USD
- Research and development 5.7 USD
- Sales and administration 19 USD
- Taxes and other 11 USD
- Net profit 4.6 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 4.6 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 81.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 12
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $23.8 is 12% above today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Specialty Segment 100%
By region
- Specialty Segment 100%
Specialty Segment brings in 100% of revenue.
Segments in detail